Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3660598019 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3660599010 | Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3660600013 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor (disorder) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3660601012 | Acute myeloid leukaemia and myelodysplastic syndrome related to topoisomerase type II inhibitor | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3660602017 | Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type II inhibitor | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3660603010 | A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukaemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukaemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective haematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. | en | Definition | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 3660604016 | A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. | en | Definition | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Sequela | false | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Therapy related acute myeloid leukemia and myelodysplastic syndrome (disorder) | false | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Associated morphology | Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type | false | Inferred relationship | Some | 1 | |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Causative agent | Topoisomerase inhibitor | true | Inferred relationship | Some | 1 | |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of chemotherapy (disorder) | true | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | After | Administration of antineoplastic agent | true | Inferred relationship | Some | 2 | |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Finding site | Bone marrow structure | true | Inferred relationship | Some | 1 | |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Due to | Administration of antineoplastic agent | true | Inferred relationship | Some | 3 | |
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of procedure | false | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Disorder following clinical procedure | false | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Complication of introduction procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Hematologic complication of procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Neoplastic complication of procedure | true | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Is a | Therapy-related myelodysplastic syndrome (disorder) | true | Inferred relationship | Some | ||
| Acute myeloid leukemia and myelodysplastic syndrome related to topoisomerase type 2 inhibitor | Associated morphology | Myeloid neoplasm post cytotoxic therapy (morphologic abnormality) | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Component annotation with string value reference set (foundation metadata concept)
FHIR